The BSGCT have launched a series of online sessions for researchers to focus on and discuss the latest developments in gene and cell therapy. The seminars are FREE to attend, and take place live and online . 


NEXT EVENT

The next Research Seminar will be announced soon.

 


PREVIOUS EVENTS

Spinal muscular atrophy - what’s next?  Watch Seminar*

* You must login or create a BSGCT user account to watch this seminar.

Wednesday 27th April 2022, 15:30-16:30 BST
Prof. Laurent Servais, University of Oxford

Three diseases modifying therapies are now approved for use by NICE, but a huge burden remains for family and patients. Indeed, SMA remains associated with a severe disability in patients diagnosed after developing symptoms.
What are the next steps? Could the association of drugs provide an additional benefit? Is there any other target that could be considered? Finally, could newborn screening constitute a valuable solution to decrease patient and societal burden in the long term?
 


Starting an academic vector core facility  Watch Seminar

A step-by-step guide to setting up and running a research-grade vector production facility within an academic institute: challenges to face, manufacturing platforms and business models for a successful vector manufacturing laboratory.

Wednesday 23rd February 2022, 14:00-15:00 GMT
Dr. Giulia Massaro, University College London

Dr Giulia Massaro is a NHIR GOSH BRC Research Fellow in Translational AAV Technology at the UCL School of Pharmacy. After her MRes in Functional Genomics at the University of Trieste and the International Centre for Genetic Engineering and Biotechnology, she joined Prof. Ahad Rahim’s Lab at UCL to complete her PhD in Gene Therapy working on rare paediatric diseases of infants. Since 2013 she has been involved in many translational gene therapy projects, collaborating with both academia and industry, focusing on rare neurological disorders with unmet medical need. In 2020 Dr Massaro opened the NeuroGTx Viral Synthesis Facility, a state-of-the-art vector production laboratory for research-grade viral vectors.  

Advanced genetic engineering of hematopoiesis: how to select the best engineering tool and expand target diseases and scope of intervention

Monday 20th September 2021, 14:00-15:00 BST
Prof. Luigi Naldini, Professor of Cell and Tissue Biology and of Gene and Cell Therapy at the San Raffaele University School of Medicine and Scientific Director of the San Raffaele Telethon Institute for Gene Therapy, Milan, Italy.

  When aiming to genetically engineer hematopoietic stem cells, translational scientists face a constantly expanding toolbox where every newly added tool promises more precise and safer performance. This talk will address how to guide the choice of the best fitting strategy for a growing range of applications among capitalizing on older tools, such as lentiviral vector mediated gene replacement, which have an established track record of successful clinical use but lack precision, or capturing the promise of targeted gene editing by artificial nucleases, which is showing preliminary but encouraging success in the clinic but still faces outstanding challenges and unknowns in the long-term, or even to embrace the newest kids in the block and venturing into the realm of break-free editors.